Pharmacodynamic bioequivalence: evaluation of different brands of terfenadine hydrochloride.
Indian J Physiol Pharmacol
;
1993 Oct; 37(4): 345-6
Article
Dans Anglais
| IMSEAR
| ID: sea-108686
ABSTRACT
Terfenadine is a selective histamine H1 receptor antagonist which binds preferentially to peripheral receptors in vivo and is devoid of central nervous system depressant activity and thus has an improved adverse effect profile (1). Hence, terfenadine may be considered to be a first line agent in the treatment of allergic rhinitis and chronic urticaria. In man terfenadine is rapidly absorbed following a single oral dose and a peak terfenadine plasma concentration is reached within 1-2 hr after the drug administration (2). The present study was carried out to compare the bioequivalence of two terfenadine hydrochloride preparations marketed by Kopran Chem. Co. and Marrel Dow U.K. (Triludan) by evaluating their ability to inhibit the skin reaction to intradermally injected histamine (3).
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
Sujet Principal:
Sujet âgé
/
Humains
/
Équivalence thérapeutique
/
Histamine
/
Méthode en double aveugle
/
Terfénadine
/
Adulte
/
Hypersensibilité immédiate
/
Adulte d'âge moyen
Type d'étude:
Essai clinique contrôlé
langue:
Anglais
Texte intégral:
Indian J Physiol Pharmacol
Année:
1993
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS